Niagen Bioscience (NAGE)
NASDAQ:NAGE
NAGE Stock Chart & Stats
$4.41
--
Market closed
$4.41
--
Day’s Range― - ―
52-Week Range$4.16 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.59M
Market Cap
$353.15M
Enterprise Value$291.18M
Total Cash (Recent Filing)$64.79M
Total Debt (Recent Filing)$2.82M
Price to Earnings (P/E)29.0
Beta0.86
Next Earnings
May 13, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding80,080,490
10 Day Avg. Volume1,310,806
30 Day Avg. Volume1,586,214
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda17.50
Forecast
1Y Price Target
$12.67Price Target Upside187.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.27
Revenue Forecast (FY)$147.92M
Bulls Say, Bears Say
Bulls Say
Demand And Revenue GrowthStrong consumer demand for Tru Niagen drove revenue and earnings above analyst expectations, and management projects continued double-digit revenue expansion, supporting sustained sales momentum.
Intellectual PropertySecuring a US patent for injectable nicotinamide riboside and acquiring additional NR patents strengthens the intellectual property portfolio, creating barriers to competition and protecting future product commercialization.
Regulatory And Legal CatalystsEngagement of an experienced FDA-focused law firm and active litigation challenging regulatory approvals could lead to the removal of competing NMN products, potentially accelerating market share gains for a science-backed Tru Niagen.
Bears Say
Earnings NormalizationNet income declined due to the absence of earlier one-time accounting benefits, indicating earnings normalization that could weigh on near-term profitability metrics.
Rising Operating CostsIncreased investments in marketing and research and development to support brand growth and new product launches will raise operating costs and could compress margins.
Sales Guidance RiskGuidance that implies sales growth below analyst expectations signals a normalization in demand and may pressure the stock until revenue trends re-accelerate.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $4.16 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $353.15M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is May 13, 2026 which is in 41 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Mar 04, 2026. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.022 by $0.028.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.08.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 80,080,490 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.05 in its last earnings report, beating expectations of $0.022. Following the earnings report the stock price went up 3.239%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (187.30% Upside)
$12.67 (187.30% Upside)
Blogger Sentiment
Neutral
NAGE Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 35.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.16%
12-Months-Change
Fundamentals
Return on Equity
26.06%
Trailing 12-Months
Asset Growth
55.84%
Trailing 12-Months
Company Description
Niagen Bioscience
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong financial performance (30% FY revenue growth, improved margins, adjusted EBITDA and cash/no debt), clear commercial momentum in Tru Niagen and expanding scientific validation and IP protection. Management also described measured, conservative guidance for 2026, planned investments in new channels (Niagen Plus injections, beauty/topical products) and continued R&D/pharma efforts (NB-4168). Key risks include increased competition and market confusion from NMN / FDA developments (now subject to litigation), some mixed clinical results (e.g., Parkinson's), higher G&A and marketing investments, and B2B revenue unpredictability. Overall, positive operational and scientific momentum outweighs the near-term regulatory, competitive and expense headwinds.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$12.67
▲(187.30% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
4.98% Insiders
8.03% Mutual Funds
4.96% Other Institutional Investors
74.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---